[go: up one dir, main page]

MX2018008185A - Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe. - Google Patents

Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.

Info

Publication number
MX2018008185A
MX2018008185A MX2018008185A MX2018008185A MX2018008185A MX 2018008185 A MX2018008185 A MX 2018008185A MX 2018008185 A MX2018008185 A MX 2018008185A MX 2018008185 A MX2018008185 A MX 2018008185A MX 2018008185 A MX2018008185 A MX 2018008185A
Authority
MX
Mexico
Prior art keywords
glucosidase
pompe disease
treatment
acid alpha
recombinant human
Prior art date
Application number
MX2018008185A
Other languages
English (en)
Other versions
MX394968B (es
Inventor
Khanna Richie
Gotschall Russell
V Do Hung
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2018008185A publication Critical patent/MX2018008185A/es
Publication of MX394968B publication Critical patent/MX394968B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para tratar la enfermedad de Pompe que incluye la administración de a-glucosidasa ácida humana recombinante que tiene una glucosilación óptima con residuos de manosa-6-fosfato junto con una cantidad de miglustat eficaz para maximizar la captación en tejidos de la a-glucosidasa ácida humana recombinante a la vez que se minimiza la inhibición de la actividad enzimática de la a-glucosidasa ácida humana recombinante.
MX2018008185A 2015-12-30 2016-12-29 Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe. MX394968B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562272890P 2015-12-30 2015-12-30
US201662300479P 2016-02-26 2016-02-26
US201662315412P 2016-03-30 2016-03-30
US201662402454P 2016-09-30 2016-09-30
US201662428867P 2016-12-01 2016-12-01
US201662431791P 2016-12-08 2016-12-08
PCT/US2016/069243 WO2017117407A1 (en) 2015-12-30 2016-12-29 Augmented acid alpha-glucosidase for the treatment of pompe disease
US15/394,135 US20170189497A1 (en) 2015-12-30 2016-12-29 Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease

Publications (2)

Publication Number Publication Date
MX2018008185A true MX2018008185A (es) 2018-08-28
MX394968B MX394968B (es) 2025-03-24

Family

ID=57822129

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008185A MX394968B (es) 2015-12-30 2016-12-29 Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.
MX2022010311A MX2022010311A (es) 2015-12-30 2018-06-29 Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010311A MX2022010311A (es) 2015-12-30 2018-06-29 Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.

Country Status (15)

Country Link
US (5) US20170189497A1 (es)
JP (4) JP2019501178A (es)
KR (3) KR102510941B1 (es)
AU (2) AU2016381832B2 (es)
BR (1) BR112018013151A2 (es)
CA (1) CA3010205A1 (es)
CL (1) CL2018001773A1 (es)
CO (1) CO2018007680A2 (es)
EA (1) EA201891507A1 (es)
IL (3) IL259876B (es)
MX (2) MX394968B (es)
MY (1) MY198085A (es)
PH (1) PH12018501313B1 (es)
SG (1) SG11201804965SA (es)
WO (1) WO2017117407A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3270894B1 (en) * 2015-03-19 2021-02-24 Translate Bio, Inc. Mrna therapy for pompe disease
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR102758570B1 (ko) * 2016-03-30 2025-01-23 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
IL319770A (en) * 2016-03-30 2025-05-01 Amicus Therapeutics Inc Method for selecting recombinant proteins with high mannose-6-phosphate content
WO2018209300A1 (en) * 2017-05-12 2018-11-15 Duke University Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy
EP3624831B1 (en) * 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2019222663A1 (en) 2018-05-17 2019-11-21 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
AU2020343680A1 (en) 2019-09-06 2022-03-24 Amicus Therapeutics, Inc. Method for capturing and purification of biologics
JP2023507575A (ja) 2019-12-20 2023-02-24 コデクシス， インコーポレイテッド 操作された酸性アルファ－グルコシダーゼバリアント
JP2023530112A (ja) 2020-06-14 2023-07-13 ジェンザイム・コーポレーション 遅発型ポンペ病を処置するための組成物及び方法
KR20230155622A (ko) * 2021-02-11 2023-11-10 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 인간 산성 알파-글루코시다제 및 이의 용도
DE102021124655A1 (de) 2021-09-23 2023-03-23 Mühlbauer Technology Gmbh Verfahren zur Nachbehandlung von gedruckten 3-D-Objekten
JP2025515159A (ja) * 2022-05-05 2025-05-13 アミカス セラピューティックス インコーポレイテッド ポンペ病の治療方法
WO2025064350A1 (en) * 2023-09-18 2025-03-27 AskBio Inc. Therapeutic adeno-associated virus using nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with heterologous signal peptide

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US20020013953A1 (en) 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US20020073438A1 (en) 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
CA2309321A1 (en) 1997-11-10 1999-05-20 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ATE410506T1 (de) 1998-12-07 2008-10-15 Genzyme Corp Behandlung der pompeschen krankheit
CA2362914C (en) 1999-02-12 2009-04-14 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
CA2378776A1 (en) 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
TWI280882B (en) 2000-07-18 2007-05-11 Univ Duke Composition for the treatment of glycogen storage disease type-II
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
WO2002087510A2 (en) 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
MXPA04003640A (es) 2001-10-16 2005-04-11 Rxkinetix Inc Formulaciones de proteina de alta concentracion y metodo de fabricacion.
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
AU2003224880A1 (en) 2002-04-05 2003-10-27 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
DK1589993T3 (en) 2003-01-31 2015-03-09 Sinai School Medicine COMBINATION THERAPY FOR TREATMENT OF PROTEIN FAILURE DISORDERS
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2005211775B2 (en) 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
CA2553955C (en) 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
CA2612538C (en) 2005-05-17 2015-06-30 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
JP2010509344A (ja) 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
ES2744574T3 (es) 2007-01-18 2020-02-25 Genzyme Corp Oligosacáridos que comprenden un grupo aminooxi y conjugados de los mismos
WO2008112525A2 (en) 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2252288A1 (en) 2007-11-21 2010-11-24 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
PL3470077T3 (pl) 2008-02-12 2021-04-06 Amicus Therapeutics, Inc. Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi
WO2009114679A2 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
AU2009223125A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for Pompe disease
PT2279210T (pt) 2008-05-07 2017-07-10 Biomarin Pharm Inc Péptidos de direcionamento lisossomal e suas utilizações
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010056746A1 (en) 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
ES2735023T3 (es) 2008-12-16 2019-12-13 Genzyme Corp Intermedios sintéticos para preparar conjugados de oligosacáridos-proteínas
WO2010096369A1 (en) 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
NZ595629A (en) 2009-04-09 2013-04-26 Amicus Therapeutics Inc Methods for preventing and/or treating lysosomal storage disorders
ES2585584T3 (es) 2009-05-26 2016-10-06 Amicus Therapeutics, Inc. Utilización de chaperonas farmacológicas para mejorar la fabricación y la purificación de ß-glucosidasa ácida
ES2758827T3 (es) 2009-06-17 2020-05-06 Biomarin Pharm Inc Formulaciones para enzimas lisosómicas
CN102712914A (zh) 2009-09-29 2012-10-03 根特大学 水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
CN103328646B (zh) 2010-09-29 2021-06-18 奥克西雷恩英国有限公司 能够使甘露糖-1-磷酸-6-甘露糖连接脱帽并使磷酸化的n-聚糖脱甘露糖基化的甘露糖苷酶及促进糖蛋白的哺乳动物细胞摄取的方法
SG10201605874TA (en) * 2011-04-22 2016-09-29 Genzyme Corp Modified acid alpha glucosidase with accelerated processing
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
US9512463B2 (en) 2011-11-08 2016-12-06 University Of Washington Methods and compositions for assaying the activity of one or more lysosomal enzymes
BR112014014808A2 (pt) * 2011-12-22 2018-09-25 Centogene Ip Gmbh combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação
US9404100B2 (en) 2012-03-07 2016-08-02 Amicus Therapeutics, Inc. High concentration alpha-glucosidase compositions for the treatment of Pompe disease
EP2825193B1 (en) 2012-03-15 2019-11-13 Oxyrane UK Limited Methods and materials for treatment of pompe's disease
HRP20210398T1 (hr) 2012-05-03 2021-05-28 Amicus Therapeutics, Inc. Režimi doziranja za liječenje pompeove bolesti
CA2915127A1 (en) 2012-06-06 2013-12-12 Giancarlo PARENTI Allosteric chaperones and uses thereof
EP2874648A4 (en) 2012-07-17 2015-12-30 Amicus Therapeutics Inc CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN
EP2943200B9 (en) 2013-01-09 2020-07-22 Amicus Therapeutics, Inc. Stable parenteral dnj compositions
US11571407B2 (en) 2013-12-23 2023-02-07 Bcn Peptides, S.A. Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis
TWI529396B (zh) 2014-07-18 2016-04-11 Mpi Corp Probe card and its transfer circuit board and signal feed structure
ES2967620T3 (es) 2014-09-30 2024-05-03 Amicus Therapeutics Inc Alfa-glucosidasa ácida altamente potente con carbohidratos potenciados
WO2017049161A1 (en) 2015-09-18 2017-03-23 Duke University ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR102758570B1 (ko) 2016-03-30 2025-01-23 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
IL319770A (en) 2016-03-30 2025-05-01 Amicus Therapeutics Inc Method for selecting recombinant proteins with high mannose-6-phosphate content

Also Published As

Publication number Publication date
IL283837A (en) 2021-07-29
US20170189497A1 (en) 2017-07-06
AU2024200071A1 (en) 2024-02-01
MY198085A (en) 2023-07-31
CA3010205A1 (en) 2017-07-06
US20180228877A1 (en) 2018-08-16
US10857212B2 (en) 2020-12-08
AU2016381832A1 (en) 2018-06-28
NZ784003A (en) 2025-06-27
IL259876B (en) 2021-06-30
IL299470A (en) 2023-02-01
US20220370571A1 (en) 2022-11-24
WO2017117407A1 (en) 2017-07-06
KR102747683B1 (ko) 2024-12-31
JP7358446B2 (ja) 2023-10-10
KR20180099753A (ko) 2018-09-05
JP2024009829A (ja) 2024-01-23
PH12018501313A1 (en) 2019-02-27
AU2016381832B2 (en) 2024-01-25
CO2018007680A2 (es) 2018-08-10
BR112018013151A2 (pt) 2018-12-18
KR20250007693A (ko) 2025-01-14
KR102510941B1 (ko) 2023-03-20
US20210268074A1 (en) 2021-09-02
US11278601B2 (en) 2022-03-22
IL299470B1 (en) 2026-01-01
IL283837B2 (en) 2023-06-01
JP2025163019A (ja) 2025-10-28
JP7707251B2 (ja) 2025-07-14
SG11201804965SA (en) 2018-07-30
JP2019501178A (ja) 2019-01-17
KR20230041833A (ko) 2023-03-24
US12414985B2 (en) 2025-09-16
NZ743230A (en) 2025-06-27
PH12018501313B1 (en) 2024-01-26
IL259876A (en) 2018-07-31
MX2022010311A (es) 2022-09-19
MX394968B (es) 2025-03-24
US20250381254A1 (en) 2025-12-18
CL2018001773A1 (es) 2018-08-24
EA201891507A1 (ru) 2018-12-28
JP2022058423A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
MX2018008185A (es) Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
BR112017002741A2 (pt) peptídeos contendo manose-6-fosfato fundidos a enzimas lisossômicas
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
MX2018007227A (es) Tratamiento de colestasis intrahepatica y enfermedades hepaticas relacionadas.
MX2020000467A (es) Compuestos retinoides y rexinoides inmunomoduladores en combinacion con inmunomoduladores para inmunoterapia contra cancer.
EP4285988A3 (en) Treating fibrosis by inhibiting tl1a
HK1256423A1 (zh) 纤维化治疗
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
CO2019012484A2 (es) Disminución de homocisteína mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
WO2016134257A8 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
CO2017001899A2 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака
AU2016303622A8 (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
MY205171A (en) Methods of treatment of hypertriglyceridemia
PH12016000355B1 (en) Use of xanthophylls for the treatment of cancers
EP4285902A3 (en) Augmented acid alpha-glucosidase for the treatment of pompe disease
BR112018016874A2 (pt) métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc)
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
EA201491048A1 (ru) Соединения двухцепочечных рнк к casp2 и их применение
UA104019U (ru) Способ лечения хронической сердечной недостаточности
EA201892473A1 (ru) In vivo использование хондроитиназы и/или гиалуронидазы для улучшения доставки агента
AR107277A1 (es) a-GLUCOSIDASA CON MAYOR CANTIDAD DE ÁCIDO PARA EL TRATAMIENTO DE LA ENFERMEDAD DE POMPE